Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
$4.41
$1.35
$50.10
$3.66M1.04227,964 shs650,294 shs
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$9.23
-2.6%
$7.94
$5.01
$18.71
$55.02M0.18117,330 shs23,402 shs
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$3.65
-2.7%
$4.10
$2.55
$6.42
$182.51M1.0810,406 shs5,487 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$8.47
-1.7%
$6.16
$3.85
$8.75
$680.69M1.24405,701 shs519,251 shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$10.97
+1.9%
$9.11
$6.44
$17.00
$845.64M0.61895,153 shs2.30 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
0.00%0.00%0.00%0.00%-92.21%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
0.00%+15.23%+5.97%+66.91%+2.33%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.00%-4.45%-9.43%+7.67%-16.34%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.00%+12.86%+28.53%+62.88%+104.59%
Replimune Group, Inc. stock logo
REPL
Replimune Group
0.00%+16.08%+10.92%+49.25%+26.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
1.1588 of 5 stars
3.80.00.00.00.60.00.0
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.5544 of 5 stars
3.33.00.04.73.82.50.6
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
2.3218 of 5 stars
3.55.00.00.02.10.00.0
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
4.2702 of 5 stars
3.51.00.04.83.22.50.6
Replimune Group, Inc. stock logo
REPL
Replimune Group
4.0717 of 5 stars
3.61.00.04.52.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
3.50
Strong Buy$6.00∞ Upside
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.57
Moderate Buy$17.7592.31% Upside
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
3.00
Buy$13.00256.16% Upside
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
3.00
Buy$24.00183.35% Upside
Replimune Group, Inc. stock logo
REPL
Replimune Group
3.13
Buy$20.8389.91% Upside

Current Analyst Ratings Breakdown

Latest ATRA, REPL, APTO, GNFT, and MGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
6/20/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
6/2/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.00
5/14/2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $35.00
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/A($0.19) per shareN/A
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$128.94M0.43N/AN/A($16.89) per share-0.55
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$67.00M2.72$0.07 per share52.18$1.50 per share2.43
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$34.51M19.73N/AN/A$0.87 per share9.74
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/A$5.40 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/A
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$147.79M-$2.32N/A22.29N/A-484.90%-241.05%-62.93%8/11/2025 (Estimated)
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$247.30M-$3.07N/AN/AN/AN/A-57.98%-45.21%8/14/2025 (Estimated)

Latest ATRA, REPL, APTO, GNFT, and MGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2025Q4 2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$0.75-$0.82-$0.07-$0.82N/AN/A
5/15/2025Q1 2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million
5/13/2025Q1 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/AN/A
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/A
1.05
1.05
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
0.57
0.57
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.08
1.23
1.23
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.34
1.53
1.51
Replimune Group, Inc. stock logo
REPL
Replimune Group
0.17
7.95
7.95

Institutional Ownership

CompanyInstitutional Ownership
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
26.62%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
2.24%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
Replimune Group, Inc. stock logo
REPL
Replimune Group
92.53%

Insider Ownership

CompanyInsider Ownership
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
1.33%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.00%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
4.20%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.50%
Replimune Group, Inc. stock logo
REPL
Replimune Group
8.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
312.14 million63.45 millionNo Data
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3305.96 million5.72 millionOptionable
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
12050.00 million47.90 millionNot Optionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30080.37 million74.34 millionOptionable
Replimune Group, Inc. stock logo
REPL
Replimune Group
21077.09 million70.30 millionOptionable

Recent News About These Companies

Replimune Group, Inc. (REPL) - Yahoo Finance
Q4 2025 Replimune Group Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aptose Biosciences stock logo

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$9.23 -0.25 (-2.64%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$9.32 +0.09 (+1.02%)
As of 07/11/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

GENFIT stock logo

GENFIT NASDAQ:GNFT

$3.65 -0.10 (-2.67%)
As of 07/11/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$8.47 -0.15 (-1.74%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$8.52 +0.04 (+0.53%)
As of 07/11/2025 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Replimune Group stock logo

Replimune Group NASDAQ:REPL

$10.97 +0.20 (+1.86%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$11.12 +0.15 (+1.32%)
As of 07/11/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.